Welcome to NDA’s seminar on 21st May 08:30-13:00 on Optimizing Value – Regulatory and Market Access Considerations.
NDA would like to invite you to join Professor Steffen Thirstrup and Professor Mira Pavlovich-Ganascia share their experiences and provide their insights and considerations to optimize the value of your development program.
The market access environment is getting increasingly challenging. The ability to develop plans and strategies for access, for today as well as tomorrow, is critical to bring new medicines to patients.
08:30 Registration and light breakfast
09:00 Welcome – Claes Buxfeldt, Director NDA HTA Advisory Board
09:30 Session one: Challenges on development programs for new drugs – Professor Steffen Thirstrup
10:00 Coffee and mingle
10:30 Session 2: HTA and Europe – where are we heading? – Professor Mira Pavlovich – Ganascia
11:00 Question and answer session
11:30 Concluding remarks and take home messages
12:00 – 13:00 Ask the Experts – Book a 20 min slot to speak directly with our experts, email: email@example.com
About the speakers
Professor Steffen Thirstrup,
Director NDA Advisory Board, Former Head of Division, Medicines Assessment and Clinical Trials, Danish Health and Medicines Authority, and CHMP member. Steffen is an expert in clinical development and regulatory strategies.
Professor Mira Pavlovich-Ganascia,
NDA HTA Advisory Board member, practicing physician and former Deputy Director for Health Technology Assessment at the Hauté Autorité de Santé (HAS), France. Mira is an expert in HTA activities related to early dialogues with developers, disease-specific guidelines and methodology of assessment for reimbursement purposes.
HTA Director at NDA Group, former Global Price & Reimbursement Director in Respiratory & Inflammation at AstraZeneca. Claes has 20 years’ experience in the market access and health economic areas and has extensive experience in developing the market access strategy/payer strategy/payer evidence generation for drug development programs from pre- clinical to launch phase.
- How to secure value in your development program considering both regulatory and market access requirements
- Learn about how, when and why it is critical to consider HTA and market access requirements in your development program
- Understand how to mitigate differences in demands/requirements between regulatory and HTA bodies
When: Tuesday 21st May 2019
Time: 08:30 – 13:00 (opportunity to book 1-1 meetings from 12:00)
Venue: SciLifelabs, Tomtebodavägen 23a, 171 65 Solna, Sweden
The seminar will be an open and interactive workshop with the opportunity to ask our presenters questions.
Specific questions can also be sent in advance to firstname.lastname@example.org. Indicate if you would like to discuss them openly during the meeting; otherwise we can book separate meetings to discuss them after the seminar.
Registration: RSVP by Friday 17th May 2019 to email@example.com
Contact: Denise Strömquist, Marketing and Management Coordinator, +46 (0)8 590 778 00, or email firstname.lastname@example.org
The seminar is free however if you are unable to attend, please advise us no later than two days before the seminar.
We look forward to seeing you there!